Madhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.
Madhuri Vusirikala, MD
Advertisement
Articles by Madhuri Vusirikala, MD
Madhuri Vusirikala, MD, discusses the role of transplant in acute lymphoblastic leukemia.
Madhuri Vusirikala, MD, professor of internal medicine in the Division of Hematology/Oncology at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses ongoing research with blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).
Madhuri Vusirikala, MD, discusses the role of minimal residual disease in acute lymphoblastic leukemia.
Advertisement
Latest Updated Articles
Dr. Vusirikala on the Role of MRD in ALLPublished: January 23rd 2020 | Updated:
Dr. Vusirikala on Ongoing Research With Blinatumomab in ALLPublished: January 28th 2020 | Updated:
Dr. Vusirikala on the Role of Transplant in ALLPublished: February 11th 2020 | Updated:
Dr. Vusirikala on Hyper-CVAD Plus Ponatinib in Philadelphia Chromosome-Positive ALLPublished: February 25th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5